Home › Funds › NAN FUNG TRINITY (HK) Ltd › BCRX
NAN FUNG TRINITY (HK) Ltd position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
NAN FUNG TRINITY (HK) Ltd reported holding 938,200 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$7.8M, representing 0.75% of its reported portfolio and ranking #45 among its reported holdings. NAN FUNG TRINITY (HK) Ltd has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NAN FUNG TRINITY (HK) Ltd's BCRX position evolved
NAN FUNG TRINITY (HK) Ltd first disclosed a stake in BCRX in Q2 2026 at 450,000 shares (US$4.5M). The position peaked in Q3 2026 at 938,200 shares, worth US$7.8M. Across 2 filings, NAN FUNG TRINITY (HK) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 938,200 shares valued at US$7.8M — an increase of 488,200 shares quarter over quarter.. Notable position changes include a 108% increase in Q3 2026 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 450.00K | $4.50M | New |
| Q3 2026 | 938.20K | $7.82M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Jones Hill Capital LP 7.08M sh · $59.00M · Q3 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M sh · $25.23M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M sh · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M sh · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M sh · $18.66M · Q2 2026
- Parkman Healthcare Partners LLC 1.62M sh · $16.24M · Q2 2026
More on NAN FUNG TRINITY (HK) Ltd
FAQ
How long has NAN FUNG TRINITY (HK) Ltd held BCRX?
NAN FUNG TRINITY (HK) Ltd has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is NAN FUNG TRINITY (HK) Ltd's current position in BCRX?
As of Q3 2026, NAN FUNG TRINITY (HK) Ltd holds 938.20K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $7.82M, representing 0.75% of its reported portfolio and ranking #45.
Has NAN FUNG TRINITY (HK) Ltd been buying or selling BCRX?
In the latest 13F filing (Q3 2026), NAN FUNG TRINITY (HK) Ltd increased its position in BCRX. The position peaked in Q3 2026 at 938.20K shares.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.